Skip to main content
. Author manuscript; available in PMC: 2017 Jul 15.
Published in final edited form as: Clin Cancer Res. 2016 Feb 5;22(14):3630–3642. doi: 10.1158/1078-0432.CCR-15-1434

Figure 5. EMT is not associated with tumor mutational burden.

Figure 5

Non-silent mutational rate, transversion rate and TP53 mutation of TCGA lung adenocarcinoma samples were included in the analysis. (A) Spearman correlation between non-silent mutational rate per Mb and EMT score. (B) Non-silent mutational rate in “epithelial” versus “mesenchymal” lung adenocarcinoma. (C) Non-silent mutational rate in TP53 mutant versus TP53 wild-type lung adenocarcinoma. (D) Non-silent mutational rate in TP53 mutant versus wild-type lung adenocarcinoma further separated by molecular smoking exposure via transversion high and low. (E) Non-silent mutational rate in “epithelial” versus “mesenchymal” lung adenocarcinoma further separated by molecular smoking exposure via transversion high and low.